Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Up 1,816.7% in April

Palisade Bio, Inc. (NASDAQ:PALI) was the recipient of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 34,500 shares, an increase of 1,816.7% from the March 31st total of 1,800 shares. Based on an average daily trading volume, of 1,030,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 4.1% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Maxim Group restated a “buy” rating and issued a $22.50 target price on shares of Palisade Bio in a research note on Tuesday, April 16th.

Palisade Bio Stock Down 2.9 %

Shares of NASDAQ:PALI traded down $0.18 during midday trading on Friday, reaching $6.05. 266,852 shares of the company traded hands, compared to its average volume of 2,816,004. Palisade Bio has a 12 month low of $3.82 and a 12 month high of $36.60. The firm has a market capitalization of $5.15 million, a price-to-earnings ratio of -0.22 and a beta of 1.33. The firm’s fifty day moving average price is $5.72 and its two-hundred day moving average price is $7.51.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings data on Tuesday, March 26th. The company reported ($3.75) earnings per share (EPS) for the quarter. Analysts forecast that Palisade Bio will post -12.29 earnings per share for the current year.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults.